[go: up one dir, main page]

AU2005692A - Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer - Google Patents

Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer

Info

Publication number
AU2005692A
AU2005692A AU20056/92A AU2005692A AU2005692A AU 2005692 A AU2005692 A AU 2005692A AU 20056/92 A AU20056/92 A AU 20056/92A AU 2005692 A AU2005692 A AU 2005692A AU 2005692 A AU2005692 A AU 2005692A
Authority
AU
Australia
Prior art keywords
cancer
treatment
methods
pharmaceutical compositions
designing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU20056/92A
Inventor
Ira Daar
Marianne Oskarsson
Nicholas Schulz
George F Van Woude
Renping Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
National Aeronautics and Space Administration NASA
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Aeronautics and Space Administration NASA, US Department of Health and Human Services filed Critical National Aeronautics and Space Administration NASA
Publication of AU2005692A publication Critical patent/AU2005692A/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU20056/92A 1991-05-08 1992-05-08 Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer Abandoned AU2005692A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69692391A 1991-05-08 1991-05-08
US696923 1991-05-08

Publications (1)

Publication Number Publication Date
AU2005692A true AU2005692A (en) 1992-12-21

Family

ID=24799069

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20056/92A Abandoned AU2005692A (en) 1991-05-08 1992-05-08 Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer

Country Status (2)

Country Link
AU (1) AU2005692A (en)
WO (1) WO1992019765A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014787A1 (en) * 1992-01-31 1993-08-05 The Trustees Of Columbia University In The City Of New York Taxol as a radiation sensitizer
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
GB2269319B (en) * 1992-08-03 1997-04-09 Bristol Myers Squibb Co Methods for administration of taxol
FR2697752B1 (en) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Antitumor compositions containing taxane derivatives.
FR2698871B1 (en) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa New taxoids, their preparation and the pharmaceutical compositions containing them.
US6441026B1 (en) 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
WO1997001344A2 (en) * 1995-06-27 1997-01-16 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
US6274576B1 (en) 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
EP1318794A2 (en) 2000-09-22 2003-06-18 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies

Also Published As

Publication number Publication date
WO1992019765A1 (en) 1992-11-12

Similar Documents

Publication Publication Date Title
HUP9902068A3 (en) Methods and compositions for the diagnosis and treatment of cancer
AU3691793A (en) Gas well treatment compositions and methods
ZA957483B (en) Compounds and methods for the treatment of cancer
AU2187992A (en) Composition and method for disease treatment
AU5606494A (en) Methods and pharmaceutical compositions for enhanced cardiopulmonary resuscitation
AU6592390A (en) Method and apparatus for the treatment of cancer
AU3519893A (en) Antitumor compositions and methods of treatment
AU8044491A (en) Antitumor compositions and methods of treatment
SK60895A3 (en) Taxane derivatives and process for their preparation
AU3406893A (en) Method and composition for the treatment of osteoporosis
AU8192691A (en) Method of treatment and compositions therefore
IL101410A0 (en) Formulation for the treatment of cancer
AU2821295A (en) Compositions and methods for the treatment of tumors
IL101245A0 (en) Pharmaceutical compositions for the treatment of prostatic cancer
AU2005692A (en) Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer
IL115320A0 (en) Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
AU7770991A (en) Method and composition for the treatment of cancer
AU3973793A (en) Method of treating cancer
IL106763A0 (en) Pharmaceutical compositions for treating cancer
GB9112552D0 (en) Method and composition for the treatment of cancer
GB9007763D0 (en) Method and composition for the treatment of cancer
GB9123572D0 (en) Pharmaceutical compositions and methods for the treatment of malignancy
EP0478660A4 (en) Pharmaceutical compositions and methods for treating inflammation
AU6358994A (en) Method of cancer treatment
GB9024181D0 (en) Pharmaceutical compositions and methods for the treatment of malignancy